Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has provided an announcement.
Infant Bacterial Therapeutics AB has partnered with Recipharm Advanced Bio to initiate the Process Performance Qualification (PPQ) for its lead product, IBP-9414, at Recipharm’s facility in Cuxhaven, Germany. This collaboration marks a significant milestone in IBT’s journey to bring IBP-9414 to market, with the potential to save over 1,000 lives annually in the US alone. The partnership underscores both companies’ commitment to addressing unmet medical needs in vulnerable populations and strengthens IBT’s commercial supply chain capabilities.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company based in Stockholm, focused on developing and commercializing drugs for diseases affecting premature babies. Its lead product, IBP-9414, is a formulated bacterial strain found in human breast milk, aimed at reducing mortality and gastrointestinal injury in premature infants. IBT’s portfolio also includes drug candidates for treating gastroschisis, preventing retinopathy of prematurity, and eliminating antibiotic-resistant infections.
Average Trading Volume: 14,511
Technical Sentiment Signal: Sell
Current Market Cap: SEK627.8M
See more insights into IBT.B stock on TipRanks’ Stock Analysis page.